Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2025 09:00 ET | Source: Baylor Genetics

Baylor Genetics Applauds New Guidance from American Academy of Pediatrics for Genome and Exome Sequencing to be used as First-Tier Tests for Children with Certain Developmental Delays

Baylor Genetics, a leading clinical diagnostic laboratory at the forefront of genetic testing, today announced its support for the American Academy of Pedi
June 17, 2025 05:00 ET | Source: EVERZOM

Lauréat de l’appel à projet Biothérapies et Bioproduction, du plan France 2030, EVerZom reçoit un financement de l’Etat de 3 millions d’euros pour industrialiser sa technologie de bioproduction d’exosomes

Lauréat de l’appel à projet Biothérapies et Bioproduction, du plan France 2030, EVerZom reçoit un financement de l’Etat de 3 millions d’euros pour industrialiser sa technologie de bioproduction...
June 10, 2025 08:56 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal...
June 06, 2025 06:04 ET | Source: Janssen Cilag International NV

AKEEGA® (niraparib e abiraterone acetato): la compressa a doppia azione di Johnson & Johnson è la prima combinazione di PARP inibitori a mostrare una migliore efficacia nei pazienti affetti da mHSPC con mutazioni dei geni HRR rispetto all’attuale standard di cura

I risultati dello studio di Fase 3 AMPLITUDE mettono in luce il potenziale di niraparib e abiraterone acetato nel ritardare la progressione del cancro e il peggioramento dei sintomi1 I dati mostrano...
June 06, 2025 06:04 ET | Source: Janssen Cilag International NV

AKEEGA® (niraparib und abirateronacetat-Doppelwirkstofftablette) von Johnson & Johnson ist der erste PARP-Inhibitor-Kombinationswirkstoff mit verbesserter Wirksamkeit bei Patienten mit HRR-mutiertem mHSPC im Vergleich zur aktuellen Standardtherapie

Die Ergebnisse der Phase III-Studie AMPLITUDE zeigen das Potenzial von niraparib und abirateronacetat zur Verzögerung des Fortschreitens der Krebserkrankung und der Verschlechterung der Symptome1 ...
June 06, 2025 06:04 ET | Source: Janssen Cilag International NV

AKEEGA® (comprimé d’acétate d’abiratérone et de niraparib à double action) de Johnson & Johnson est la première association d’inhibiteurs de PARP à montrer une meilleure efficacité chez les patients atteints d’un CPHSm avec mutation du mécanisme RH par rapport au traitement de référence

Les résultats de l’étude de la Phase 3 AMPLITUDE montrent que le niraparib et l’acétate d’abiratérone peuvent retarder la progression du cancer et l’aggravation des symptômes1 Les données montrent...
June 03, 2025 10:45 ET | Source: Janssen Cilag International NV

Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction...
June 02, 2025 10:30 ET | Source: Exactitude Consultancy

Podiatry Instruments Market to Hit $2.2 Billion by 2034, Driven by 6.6% CAGR | Exactitude Consultancy

Luton, Bedfordshire, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Market Overview The global podiatry instruments market is valued at approximately $1.2 billion in 2024 and is projected to...
May 08, 2025 08:00 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Announces 15 Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting

Research Triangle Park, N.C., May 08, 2025 (GLOBE NEWSWIRE) --Three oral and 12 poster presentations demonstrate breadth and progress of AskBio’s gene therapy research and development...
May 02, 2025 04:09 ET | Source: Research and Markets

Orthopedic Implants Market and Companies Overview 2025: A $32.4 Billion Competitive Landscape by 2030, Featuring Detailed Profiles of 29 Major Companies

Dublin, May 02, 2025 (GLOBE NEWSWIRE) -- The "Orthopedic Implants - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.Valued at US$25.3 billion in 2024, the...